MedTrace Logo

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

NCT06030258 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-04-30

No results posted yet for this study

Summary

This is a multicenter, open-label, Randomized, phase Ib/II clinical study to evaluate the anti-tumor efficacy, safety, tolerability, and PK of IN10018 in combination with anti-PD-1/L1 monoclonal antibody (Tislelizumab is proposed as the combination drug) and chemotherapy (platinum and etoposide) as the first-line treatment in Extensive-stage small cell lung cancer (ES-SCLC).

Conditions

  • Small Cell Lung Cancer Extensive Stage

Interventions

DRUG

IN10018

orally taken once daily

DRUG

Tislelizumab

200mg D1, Q3W, intravenously

DRUG

Carboplatin

AUC 5 mg/ml/min, D1, Q3W, intravenously

DRUG

Etoposide

Etoposide 100 mg/m2, D1-D3, Q3W, intravenously

Sponsors & Collaborators

  • InxMed (Shanghai) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jun Zhao · Peking University Cancer Hospital & Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-30
Primary Completion
2025-12-24
Completion
2025-12-24

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06030258 on ClinicalTrials.gov